Connect with us

Technology

Clarivate Identifies Eleven Potential Blockbuster and Transformative Drugs in Annual Drugs to Watch Report

Published

on

Anticipated advancements in obesity, oncology, gene therapy and other areas poised to revolutionize patient care

LONDON, Jan. 8, 2025 /PRNewswire/ — Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, today announced the release of the twelfth annual Drugs to Watch™ report, a trusted guide to the therapies poised to redefine the future of healthcare. This year, the highly anticipated resource highlights 11 drugs projected to achieve blockbuster status or revolutionize treatment paradigms within five years. Since its inception, Drugs to Watch has identified over 98 transformative therapies, cementing its role as an essential resource for navigating the ever-evolving pharmaceutical landscape.

This year’s report, powered by insights from the Clarivate Cortellis intelligence suite of products, highlights 11 therapies that have recently launched or are set to debut in 2025. These innovations, addressing critical challenges in areas such as obesity, oncology, and gene therapy, are forecast to achieve blockbuster sales by 2030 or dramatically improve patient outcomes on a global scale. The report also explores pivotal trends shaping the industry, including the surging demand for obesity treatments, the transformative potential of gene editing, and the growing impact of regulatory innovation.

The report offers an in-depth analysis of the chronic disease market in Mainland China, spotlighting five therapies expected to exceed $1 billion in annual sales over the next five years or deliver transformative outcomes for patients. It also explores critical topics shaping global healthcare, including regulatory advancements, the role of radiopharmaceutical theranostics in oncology, and the growing use of real-world data (RWD) and patient-reported outcomes (PROs) to drive health equity and enhance regulatory submissions.

Henry Levy, President, Life Sciences & Healthcare, Clarivate, remarked: “Innovation in the life sciences is reaching unprecedented heights, and this year’s Drugs to Watch™ report once again demonstrates the industry’s ability to deliver therapies that address unmet medical needs and challenge existing paradigms of care. At Clarivate, we take pride in the precision and reliability of our predictions—last year, we identified 13 molecules as Drugs to Watch, with 12 already approved and launched and one poised for launch. This track record reflects the strength of our comprehensive data and deep expertise. By continuing to provide actionable insights, we empower the sector to navigate opportunities, overcome challenges and drive progress in advancing global health.”

Mike Ward, Global Head of Thought Leadership, Life Sciences & Healthcare, Clarivate, stated: “2025 represents a turning point for the life sciences sector as it embraces cutting-edge technologies such as AI and machine learning to enhance drug discovery and development. This year’s report captures the dynamic forces at play, including groundbreaking progress in precision oncology, the rise of radiopharmaceuticals, and the growing focus on addressing global health disparities.”

The 2025 Drugs to Watch™ report highlights key trends reshaping the life sciences landscape, emphasizing the transformative impact of emerging technologies and therapeutic breakthroughs. Advances in AI and machine learning are streamlining drug discovery, clinical trials, and real-world data integration, enabling precision medicine approaches. The obesity market is undergoing a revolution driven by next-generation GLP-1 therapies, while radiopharmaceutical theranostics are redefining cancer treatment with a “see it and treat it” paradigm. Gene editing technologies are unlocking new opportunities in personalized medicine, and evolving regulatory frameworks are fostering greater emphasis on patient-reported outcomes and health equity. Together, these trends showcase the sector’s resilience and its ability to navigate challenges while driving innovation to improve patient care worldwide.

This year’s drugs to watch exemplify the fusion of innovation and dedication to advancing patient care in an increasingly complex healthcare ecosystem. The Drugs to Watch™ 2025 list include:

AWIQLI® (LAI 287; insulin icodec) developed by Novo Nordisk | Type 1 and type 2 diabetes mellitus 
AWIQLI®, the first once-weekly, subcutaneous insulin, has launched in Australia, Canada, the EU, Mainland China, and Japan. Its weekly dosing offers a significant advantage over daily basal insulin, potentially reducing the treatment burden for patients with type 1 or type 2 diabetes (T1DM and T2DM).

CagriSema (cagrilintide + semaglutide) developed by Novo Nordisk | Obesity and type 2 diabetes mellitus 
CagriSema, combining cagrilintide, a long-acting amylin analog, with semaglutide, promises superior efficacy over semaglutide (OZEMPIC/WEGOVY®) and tirzepatide (MOUNJARO/ZEPBOUND®) in treating obesity and type 2 diabetes. This next-generation GLP-1 therapy leverages the benefits of GLP-1s, such as enhanced insulin secretion and appetite reduction, while incorporating amylin’s effects, including slowed glucose absorption and release. If approved, CagriSema will be the first fixed-dose combination of amylin and GLP-1 receptor agonists in the obesity and T2DM markets.

COBENFY™ (KarXT; xanomeline-trospium) developed by Bristol Myers Squibb | Schizophrenia and psychosis related to Alzheimer’s disease
Amid setbacks for emerging schizophrenia treatments, the approval of COBENFY marks a transformative milestone as the first drug in over 30 years with a novel mechanism of action for treating schizophrenia. Combining xanomeline and trospium, COBENFY selectively targets M1 and M4 receptors, rather than traditional dopamine pathways, while minimizing cholinergic side effects. While further data is needed to assess its effectiveness in Alzheimer’s disease-related psychosis, COBENFY shows strong commercial potential if proven effective in treating AD-related hallucinations and delusions.

EBGLYSS™ (lebrikizumab) developed by Eli Lilly and Co and Almirall | Atopic dermatitis
EBGLYSS™, the third biologic targeting IL-13 for atopic dermatitis, follows DUPIXENT® (dupilumab) and ADBRY®/ADTRALZA® (tralokinumab) to market. Its less frequent dosing, more selective IL-13 inhibition, and strong efficacy and safety data position it as a likely first-line treatment for moderate-to-severe atopic dermatitis when topical corticosteroids are inadequate.

Fitusiran developed by Alnylam® Pharmaceuticals Inc and Sanofi | Hemophilia A and B
Fitusiran, shown to be effective in phase 3 trials for both hemophilia A and B, regardless of inhibitor status, has the potential to offer a new approach to hemophilia treatment. This small interfering RNA (siRNA) therapy works by inhibiting SerpinPC1 mRNA, reducing antithrombin levels, promoting thrombin generation, and helping to rebalance hemostasis to prevent bleeds. Leveraging Alnylam® Pharmaceuticals’ ESC-GalNAc conjugate technology, fitusiran could become the first antithrombin-lowering therapy based on a double-stranded RNA molecule, pending approval.

GSK-3536819 (MenABCWY) developed by GSK plc | Meningococcus
GSK plc’s GSK-3536819 vaccine candidate, a 5-in-1, first-generation formulation, targets the five groups of Neisseria meningitidis (A, B, C, W, and Y) responsible for most invasive meningococcal disease (IMD) cases worldwide. It combines the antigenic components of GSK’s licensed meningococcal vaccines, BEXSERO (MenB) and MENVEO (MenACWY), both of which have established efficacy and safety profiles.

IMDELLTRA™ (tarlatamab-dlle) developed by Amgen | Small-cell lung cancer (SCLC)
IMDELLTRA™ is a first-in-class immunotherapy for extensive-stage small cell lung cancer (ES-SCLC). Using Amgen’s bispecific T cell engager (BiTE®) molecules, it targets CD3 on T cells and DLL3 on tumor cells, enabling T cells to attack and lyse the tumor. DLL3 is expressed on the surface of SCLC cells in more than 85% of patients but is minimally expressed on healthy cells making it an attractive target. This mechanism positions IMDELLTRA as a potential standard of care for previously treated ES-SCLC.

mRESVIA (mRNA-1345) developed by Moderna Inc | RSV
With its U.S. FDA approval in May 2024, mRESVIA® joined AREXVY and ABRYSVO, both featured in Drugs to Watch 2024, as respiratory syncytial virus (RSV) vaccines currently available for adults ages 60 years and older, helping further support the public health initiative to reduce the RSV-related disease burden. Even with available vaccines, RSV infections continue to be a public health concern, particularly for infants and older adults (65 years and older).

SEL-212 developed by Sobi® and Cartesian Therapeutics Inc/Selecta Biosciences Inc | Gout
SEL-212 is a novel, once-monthly treatment combining pegylated uricase (pegadricase; SEL-037) with ImmTOR™, an immune tolerance technology designed to inhibit the formation of anti-drug antibodies (ADAs). For this application, ImmTOR consists of SEL-110.36, an inhibitor of uricase-specific ADA. This approach may help overcome the limitations of reduced efficacy and tolerability seen with other biologic treatments, such as KRYSTEXXA® (pegloticase), in patients with chronic gout.

Vepdegestrant (ARV-471) developed by Arvinas Inc and Pfizer Inc | Breast cancer
A global collaboration between Arvinas Inc and Pfizer Inc, vepdegestrant may become the first PROteolysis Targeting Chimera (PROTAC®) protein degrader on the market. Designed to target and degrade the estrogen receptor (ER) protein, early studies suggest PROTAC-induced degradation is more complete than with oral selective estrogen receptor degraders (SERDs). This offers potential for overcoming endocrine resistance in breast cancer. Label expansions, including combination with IBRANCE® (palbociclib), are being explored.

Zanzalintinib (XL092) developed by Exelixis Inc | Colorectal cancer, renal cell carcinoma and squamous cell carcinoma of head and neck
Zanzalintinib is a third-generation oral tyrosine kinase inhibitor targeting VEGF receptors, MET, and TAM kinases involved in tumor growth and immunosuppression. Currently in phase 3 trials for non-clear-cell renal cell carcinoma (nccRCC), colorectal cancer (CRC) and squamous cell carcinoma of the head and neck (SCCHN), the company anticipates one potential zanzalintinib launch per year starting as early as 2026. Compared to CABOMETYX® (cabozantinib), zanzalintinib may offer benefits, including approval for nccRCC histology and a broader patient population.

Access the Drugs to Watch 2025 report from Clarivate, here.

For more Drugs to Watch updates and analyses throughout the year, visit the Drugs to Watch web page and follow Clarivate for Life Sciences & Healthcare on LinkedIn and X. Join the conversation, using #DrugstoWatch.

To learn more about how Clarivate can help healthcare companies inform and shape the drug discovery, development and delivery process, visit here.

Methodology for the Clarivate Drugs to Watch 2025 Report
To identify this year’s Drugs to Watch, Clarivate drew from the expertise of over 160 analysts covering hundreds of diseases, drugs and markets, along with 11 integrated data sets that span the R&D and commercialization lifecycle, including: Cortellis Competitive Intelligence™Disease Landscape & ForecastEpidemiology Intelligence, BioWorld™Cortellis Regulatory Intelligence™, Drug Timeline & Success Rates, Cortellis Clinical Trials Intelligence™, Cortellis Deals Intelligence™,  Access & Reimbursement payer studiesClarivate Real-World Data and AnalyticsWeb of Science™Derwent Innovation™, and other industry sources including biopharma company press releases, filings and peer-reviewed publications. Candidate drugs in phase 2 or phase 3 trials, at pre-registration or registration stage, or already launched in 2024 were selected for analysis, including both novel treatments and already-marketed drugs pursuing new indications that could be particularly impactful. Drugs launched prior to 2024 were excluded. The dataset was filtered for drugs that had total forecast sales of $1 billion or more by 2030. Clarivate experts and analysts evaluated each drug in its individual context, based on factors such as expected approval or launch dates, competitive landscape, regulatory status, trial results, market dynamics and other key factors, and added novel drugs that, while likely to fall short of blockbuster status, are poised to be therapeutic game-changers.

Please note that Clarivate analysts generated the data shown in this report prior to December 31, 2024. The Drugs to Watch 2025 Report and the treatments referenced in this release are based on Clarivate’s current expectations per existing data, but actual results derived from the drugs named in the report and here may differ significantly.

Clarivate is committed to comprehensively supporting customers across the entire drug, device and medical technology lifecycles to advance human health. By combining patient journey data, therapeutic area expertise, artificial intelligence and analytics in ways that unlock hidden insights, data-driven decisions and accelerating innovation, Clarivate’s end-to-end research intelligence is designed to enable customers to make informed evidence-based decisions. 

About Clarivate
Clarivate™ is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit www.clarivate.com.

Media Contact:
Catherine Daniel
Director, External Communications, Life Sciences & Healthcare
newsroom@clarivate.com

SOURCE Clarivate Plc

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

IMDA and Tencent Debut “Beyond the Screen” to Champion Real-World Connection through Digital Play

Published

on

By

The launch is marked by the signing of an agreement between IMDA and Tencent to advance healthy digital habits and safe, responsible use of digital technologies among youths, parents, and families.

SINGAPORE, May 2, 2026 /PRNewswire/ — The Infocomm Media Development Authority (IMDA) and Tencent today jointly launched “Beyond the Screen: Healthy Digital Play”, a new digital wellbeing campaign that encourages healthy digital habits by bringing families into the conversation and strengthening real-world connection through healthy gameplay.

The campaign encourages families to bridge the gap between play and purpose through gaming. It showcases how digital play can foster deeper understanding, facilitate balanced routines, and build stronger connections at home.

“Digital spaces are already a natural part of how young people learn, play, and connect today,” said Mr Murphy Zhao, Country Manager of Tencent Singapore and Head of Tech Group, Tencent Games. “As a company with deep expertise across digital entertainment and communications, we want to play a constructive role by helping families build meaningful digital habits that extend beyond the screen.”

Advancing Family Digital Wellness In Partnership with IMDA

As part of the launch, IMDA and Tencent also signed an agreement to strengthen collaboration on initiatives in digital wellbeing. The agreement was signed by Ms Joanna Lam, Cluster Director for Digital Readiness, IMDA, and Mr Murphy Zhao, Country Manager of Tencent Singapore and Head of Tech Group, Tencent Games. The collaboration builds on Tencent’s ongoing cooperation with IMDA, in support of the national Digital for Life (DfL) movement, focusing on promoting online safety and healthy digital habits among youths, parents, and families.

Tencent will co-develop educational content with IMDA, as well as organise four community outreach activities, reaching out to an estimated 4,000 participants. The company will also commit S$ 25,000, which totals to S$ 50,000 with the government’s dollar-to-dollar matching, to the DfL Fund. The DfL Fund provides support for projects and activities promoting digital inclusion, digital literacy and digital wellness. 

“Ensuring digital wellness is increasingly important, particularly for our children who are digital natives,” said Ms Joanna Lam, Cluster Director for Digital Readiness, IMDA. “Tencent has been a DfL partner since 2022, and I thank them for their continued commitment to the DfL cause. We look forward to deepening our collaboration with Tencent to empower parents and youths with practical guidance to build healthy digital habits and navigate the digital world safely together.”

Leading the Conversation on Healthy Digital Play

The inaugural Singapore launch event was officiated by Ms Jasmin Lau, Minister of State, Ministry of Digital Development and Information, and also hosted social service organisations from Singapore, Malaysia, Thailand, Indonesia, and the Philippines. At the event, families participated in gamified quiz experiences and took home educational materials designed to transform gaming into healthier routines at home. 

The programme also featured a parenting talk that shared practical guidance on utilising games as a bridge for conversation at home. The session highlighted how, when guided by constructive routines, gaming can support the development of soft skills such as communication, teamwork, strategic thinking, and persistence.

During the event’s expert insights session, Mr Narasimman S/O Tivasiha Mani, psychotherapist and co-founder of local youth charity Impart, said, “Healthy gaming is not built through one-off rules. It grows through rapport, shared understanding, and everyday conversations. Through a collaborative process between educators, families, and the wider community, it becomes easier to set shared expectations and support balanced habits that carry beyond the screen.”

Building a Scalable Digital Wellbeing Framework for Southeast Asia

While digital habits may look different across the region, the underlying need is the same — helping families build healthier, more confident relationships with the digital world.

“Beyond the Screen” is part of Tencent’s broader commitment to fostering intentional digital play, equipping youths, parents, and educators with practical resources to build balanced routines, encourage respectful interactions, and strengthen open communication at home.

Insights from the Singapore launch will inform the rollout of the campaign across Southeast Asia in 2026, with local adaptations to meet the needs of diverse communities in the region.

About Digital for Life Movement

A Digital Future for All – In our increasingly digital world, everyone can play a part to help create a more inclusive digital future.

The Digital for Life (DfL) national movement, launched on 8 February 2021, aims to galvanise the community across the 3Ps (Private, Public and People) to help Singaporeans embrace digital as a lifelong pursuit and enrich lives through digital technology.

The DfL fund was also set up to support projects and activities promoting digital inclusion, digital literacy and digital wellness. Learn more about the DfL movement at digitalforlife.gov.sg.

About Infocomm Media Development Authority

The Infocomm Media Development Authority (IMDA) leads Singapore’s digital transformation by developing a vibrant digital economy and an inclusive digital society. As Architects of Singapore’s Digital Future, we foster growth in Infocomm Technology and Media sectors in concert with progressive regulations, harnessing frontier technologies, and developing local talent and digital infrastructure ecosystems to establish Singapore as a digital metropolis.

For more news and information, visit www.imda.gov.sg or follow IMDA on LinkedIn (IMDAsg), Facebook (IMDAsg) and Instagram (@imdasg).

About Tencent 

Tencent is a world-leading internet and technology company that develops innovative products and services to improve the quality of life of people around the world. Our communication and social services connect more than one billion people around the world, helping them to keep in touch with friends and family, access transportation, pay for daily necessities, and even be entertained. Our financial technology business covers payment, credit, wealth management and insurance sectors, as we support our partners’ business growth and assist their digital upgrade through FinTech and other enterprise services. We also publish some of the world’s most popular video games and other high-quality digital content, enriching interactive entertainment experiences for people around the globe. Tencent was founded in Shenzhen, China, in 1998, and has been listed on the Main Board of the Stock Exchange of Hong Kong since 2004.

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/imda-and-tencent-debut-beyond-the-screen-to-champion-real-world-connection-through-digital-play-302760594.html

SOURCE IMDA; Tencent

Continue Reading

Technology

Does Your Building Have Fire Sprinklers?

Published

on

By

Fast Guard Service alerts real estate owners and property managers: 2026 fire code updates to NFPA 25 will significantly affect sprinkler system compliance requirements — and insurance implications could not be more serious.

SAN JOSE, Calif., May 2, 2026 /PRNewswire/ — Fast Guard Service, one of the nation’s leading providers of licensed fire watch and security guard services, is urging commercial and residential property owners to take immediate stock of their fire sprinkler systems as sweeping 2026 updates to NFPA 25 — the national standard governing water-based fire protection system inspection, testing, and maintenance — take effect across the country.

The timing could not be more consequential. Private insurers are exiting fire-risk markets at an accelerating pace, dropping policyholders and limiting coverage in states from California to Florida. In this environment, a sprinkler system that fails a compliance check is no longer a routine maintenance issue. It is a potential grounds for claim denial or policy cancellation.

The 2026 edition of NFPA 25 introduces several changes property owners must act on now. Fire pump failures are formally classified as system impairments requiring immediate response. Supervisory valve testing moves to a semiannual schedule. Annual internal inspections are now mandatory for all dry, preaction, and deluge valves. And where corrosion-control technology has been used to justify smaller pipe sizes, ongoing maintenance of that equipment is now a codified legal obligation — not a recommendation.

Critically, any sprinkler system impairment — whether triggered by repair, renovation, freeze damage, or a compliance-driven upgrade — legally requires a certified fire watch for the duration of the outage under NFPA 1, NFPA 101, and local fire authority mandates. This is a condition of occupancy, not an option.

“The 2026 code updates will send a wave of sprinkler systems into inspection and repair cycles,” said a spokesperson for Fast Guard Service. “Every one of those impairment windows requires a fire watch on-site. We are prepared to be there.”

Fast Guard Service deploys certified fire watch personnel 24 hours a day, 7 days a week, anywhere in the United States — typically within hours of a client’s call. Guards conduct continuous patrols, maintain documentation accepted by insurers and code enforcement authorities, and coordinate directly with fire departments when needed.

Property owners who are unsure whether their sprinkler systems meet 2026 NFPA 25 requirements are encouraged to contact Fast Guard Service for guidance.

Founded in August 2013 and headquartered in Hollywood, Florida, Fast Guard Service is a fully licensed, bonded, and insured private security company operating in all 50 states. The company specializes in armed and unarmed security guards, fire watch services, executive protection, mobile surveillance, event security, and emergency response. Fast Guard Service is trusted by Fortune 500 companies, government entities, healthcare systems, commercial developers, and private clients nationwide.

All operations are tracked through the proprietary Fast Guard App, providing clients with real-time GPS reporting, live guard location updates, and digital incident documentation.

For an instant quote or same-day service, visit www.fastguardservice.com or call (844) 254-8273.

Press Release Service provided by 24-7PressRelease.com.

View original content:https://www.prnewswire.com/news-releases/does-your-building-have-fire-sprinklers-302760491.html

SOURCE Fast Guard Service

Continue Reading

Technology

First Online Conversations Are Changing in 2026, According to New Secretmeet Research

Published

on

By

New research from Secretmeet reveals that the classic “Hey” opener is dying out — and the way people initiate connections online in 2026 looks nothing like it did just three years ago.

GIBRALTAR, May 2, 2026 /PRNewswire-PRWeb/ — People are rethinking the first move. Not just what to say, but when to say it, how long to make it, and what emotional tone to lead with. Across the board, data from Secretmeet’s latest research study shows a clear shift in how online conversations begin in 2026.

The single-word opener? Largely gone. The copy-paste compliment? People spot it instantly. Secretmeet noted that what’s replacing them is more interesting — and more human.

The Death of the One-Word Opener

For years, “Hey,” “Hi,” and “Hello 👋” dominated opening messages on dating platforms. They required no effort and, accordingly, generated little response. According to data published by the Journal of Computer-Mediated Communication, conversational openers that include a specific reference to the recipient’s profile generate significantly higher response rates than generic greetings.

Secretmeet’s research confirms the trend is accelerating. In 2026, users who open with a question — particularly one tied to something specific in a profile — see measurably stronger engagement in the first exchange. The bar for a “good” first message has risen.

This doesn’t mean people need to write an essay. Short still works. But purposeful short beats lazy short every time.

One of the more striking findings from Secretmeet: wit is winning. Openers with a light, humorous tone — a playful observation, a self-aware joke, a clever hypothetical — are outperforming earnest, serious introductions in early conversation engagement.

The Timing Shift Nobody Expected

When people send that first message matters more than most realize. In a Secretmeet review of activity trends, data points to a notable behavioral change: users in 2026 are increasingly active during morning hours — particularly between 7 a.m. and 9 a.m. — a window that was almost entirely quiet just a few years ago.

Evening hours still dominate overall volume. But morning messages show a disproportionately high response rate. The theory? People checking their phones with coffee and no agenda are more present, less distracted, and more open to genuine interaction than those scrolling at midnight.

It’s a small tactical insight with a surprisingly large emotional implication: presence matters more than timing, and mornings are when people show up fully. Secretmeet’s data makes that case clearly.

What This Means for How We Connect

The bigger picture here isn’t about tactics. It’s about expectations. People arriving at online dating platforms in 2026 want something more immediate and more genuine than they did in 2020. The pandemic years accelerated a kind of emotional directness online — and that hasn’t reversed.

People want to feel seen in a first message. They want to laugh. They want a reason to respond. A Secretmeet review of first-message engagement data suggests that users are increasingly capable of signaling — and detecting — authentic intent right from the very first line.

The opening message has always mattered. What’s changed is how clearly people understand that now.

About Secretmeet

Secretmeet is an online dating platform built around one straightforward idea: conversations should feel good. Not stressful, not performative — genuinely enjoyable. The platform is designed for people who want warmth, a little wit, and the kind of back-and-forth that actually goes somewhere. Whether you’re looking for something serious or just a spark of something new, Secretmeet reviews its features continuously to ensure that the first message has a real chance of turning into something worth remembering.

Media Contact

Alice Ross, Secretmeet, 1 14844760121, smm@secretmeet.com, https://secretmeet.com/

View original content:https://www.prweb.com/releases/first-online-conversations-are-changing-in-2026-according-to-new-secretmeet-research-302759958.html

SOURCE Secretmeet

Continue Reading

Trending